Taysha Gene Therapies, Inc. Quarterly Debt-to-equity in % from Q2 2021 to Q2 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Taysha Gene Therapies, Inc. quarterly Debt-to-equity history and growth rate from Q2 2021 to Q2 2024.
Taysha Gene Therapies, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 283 %.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q2 2024	283	+1.42K		Jun 30, 2024
Q1 2024	1.32K	-230	-14.9%	Mar 31, 2024
Q4 2023	-2.2K	-2.68K	-564%	Dec 31, 2023
Q3 2023	-604	-838	-358%	Sep 30, 2023
Q2 2023	-1.14K	-1.28K	-919%	Jun 30, 2023
Q1 2023	1.55K	+1.46K	+1777%	Mar 31, 2023
Q4 2022	475	+429	+940%	Dec 31, 2022
Q3 2022	234	+211	+923%	Sep 30, 2022
Q2 2022	139	+129	+1267%	Jun 30, 2022
Q1 2022	82.4			Mar 31, 2022
Q4 2021	45.7			Dec 31, 2021
Q3 2021	22.9			Sep 30, 2021
Q2 2021	10.2			Jun 30, 2021

* An asterisk sign (*) next to the value indicates that the value is likely invalid.